Comprehensive molecular profiling of lung adenocarcinoma
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Adenocarcinoma of the lung is the leading cause of cancer death worldwide. Here we report molecular profiling of 230 resected lung adenocarcinomas using messenger RNA, microRNA and DNA sequencing integrated with copy number, methylation and proteomic analyses. High rates of somatic mutation were seen (mean 8.9 mutations per megabase). Eighteen genes were statistically significantly mutated, including RIT1 activating mutations and newly described loss-of-function MGA mutations which are mutually exclusive with focal MYC amplification. EGFR mutations were more frequent in female patients, whereas mutations in RBM10 were more common in males. Aberrations in NF1, MET, ERBB2 and RIT1 occurred in 13% of cases and were enriched in samples otherwise lacking an activated oncogene, suggesting a driver role for these events in certain tumours. DNA and mRNA sequence from the same tumour highlighted splicing alterations driven by somatic genomic changes, including exon 14 skipping in MET mRNA in 4% of cases. MAPK and PI(3)K pathway activity, when measured at the protein level, was explained by known mutations in only a fraction of cases, suggesting additional, unexplained mechanisms of pathway activation. These data establish a foundation for classification and further investigations of lung adenocarcinoma molecular pathogenesis. An integrated transcriptome, genome, methylome and proteome analysis of over 200 lung adenocarcinomas reveals high rates of somatic mutations, 18 statistically significantly mutated genes including RIT1 and MGA, splicing changes, and alterations in MAPK and PI(3)K pathway activity. This report from The Cancer Genome Atlas Research Network presents molecular profiling of 230 resected untreated lung adenocarcinomas. Integrated analyses of transcriptome, genome, methylome and proteome collectively identify high rates of somatic mutation, significantly mutated genes including RIT1 and MGA, splicing alterations driven by somatic genomic changes, and point to as yet unidentified lesions that alter MAPK and PI(3)K pathway activity. These data establish a foundation for classification and further investigations of the leading cause of cancer death worldwide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Landmark large scale sequencing studies have established a census of major KRAS co-mutations in both early-stage and advanced LUAD15, 34, 59, 62.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutations in PIK3CA and CTNNB1 are more frequent in advanced stage tumors compared with early stage LUADs, pointing towards functional roles in malignant progression and metastasis, whereas alterations in TP53 (62.5%), RB1 (9.5 −12.5%) and NKX2–1 (12.5%) appear to occur with comparable frequencies in early- and advanced-stage tumors15, 34, 72, 73.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“earlier studies that identified a central role for WNT signaling in LUAD metastasis”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Inactivating mutations or loss of STK11/LKB1, which define one of the major genomic sub-groups of KRAS-mutant lung cancers1,19,62, are of particular interest because they are associated with decreased responsiveness to immune checkpoint blockade9,63 and poor overall prognosis64.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Importantly, large-scale profiling studies utilizing either whole exome sequencing or broad targeted sequencing panels in NSCLC tumors have revealed multiple non-random patterns of co-occurring or mutually exclusive mutations, which typically vary depending on the particular oncogenic driver mutation15, 34, 58–62.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [34]
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationMutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationSensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981
Travis, W. D., Brambilla, E., Noguchi, M., Nicholson, A. G., Geisinger, K. R., Yatabe, Y., Beer, D. G., Powell, C. A., Riely, G. J., Van Schil, P. E., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318206a221 · Cited by 4,792
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446 · cited 1×
“Analysis of mutations in PIK3CA and STK11, STK11 protein levels, and AMPK and AKT phosphorylation(33) led to the identification of three major mTOR patterns in lung adenocarcinoma: (1) tumours with minimal or basal mTOR pathway activation, (2) tumours showing higher mTOR activity accompanied by either STK11-inactivati…”
BackgroundComprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Self-citationBhattacharjee, A., Richards, W. G., Staunton, J., Li, C., Monti, S., Vasa, P., Ladd, C., Beheshti, J., Bueno, R., Gillette, M., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191502998 · Cited by 2,576
Massive genomic rearrangement acquired in a single catastrophic event during cancer development
Stephens, P. J., Greenman, C. D., Fu, B., Yang, F., Bignell, G. R., Mudie, L. J., Pleasance, E. D., Lau, K. W., Beare, D., Stebbings, L. A., et al. (2011) · Cell · doi:10.1016/j.cell.2010.11.055 · Cited by 2,414
Cited by
Items 601–700 of 1,045
Mediator kinase module and human tumorigenesis
Clark, A. D., Oldenbroek, M., & Boyer, T. (2015) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2015.1064854 · Cited by 135
Systematic discovery of complex insertions and deletions in human cancers
Ye, K., Wang, J., Jayasinghe, R., Lameijer, E.-W., McMichael, J. F., Ning, J., McLellan, M. D., Xie, M., Cao, S., Yellapantula, V., et al. (2016) · Nature Medicine · doi:10.1038/nm.4002 · Cited by 117
Tagal, V., Wei, S., Zhang, W., Brekken, R. A., Posner, B. A., Peyton, M., Girard, L., Hwang, T., Wheeler, D. A., Minna, J. D., et al. (2017) · Nature Communications · doi:10.1038/ncomms14098 · Cited by 129
The dawn of the liquid biopsy in the fight against cancer
Domínguez-Vigil, I. G., Moreno-Martínez, A. K., Wang, J. Y., Roehrl, M. H. A., & Barrera-Saldaña, H. A. (2017) · Oncotarget · doi:10.18632/oncotarget.23131 · Cited by 133
The Case for Proteomics and Phospho‐Proteomics in Personalized Cancer Medicine
Doll, S., Gnad, F., & Mann, M. (2019) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201800113 · Cited by 117
Metabolic Regulation of Redox Balance in Cancer
Purohit, V., Simeone, D. M., & Lyssiotis, C. A. (2019) · Cancers · doi:10.3390/cancers11070955 · Cited by 117
Lim, R. J., Salehi‐Rad, R., Tran, L. M., Oh, M. S., Dumitras, C., Crosson, W. P., Li, R., Patel, T. S., Man, S., Yean, C. E., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101479 · Cited by 173
MEK and PI3K inhibition in solid tumors: rationale and evidence to date
Jokinen, E., & Koivunen, J. P. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015571111 · Cited by 116
Augert, A., Zhang, Q., Bates, B., Cui, M., Wang, X., Wildey, G., Dowlati, A., & MacPherson, D. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.12.011 · Cited by 115
TGFβ pathway inhibition in the treatment of non-small cell lung cancer
Eser, P. Ö., & Janne, P. A. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.11.004 · Cited by 122
Wang, C., Yin, R., Dai, J., Gu, Y., Cui, S., Ma, H., Zhang, Z., Huang, J., Qin, N., Jiang, T., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04492-2 · Cited by 116
A Human Adult Stem Cell Signature Marks Aggressive Variants across Epithelial Cancers
Smith, B. A., Balanis, N. G., Nanjundiah, A., Sheu, K. M., Tsai, B. L., Zhang, Q., Park, J. W., Thompson, M. J., Huang, J., Witte, O. N., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.08.062 · Cited by 141
MYC, MYCL, and MYCN as therapeutic targets in lung cancer
Massó-Vallés, D., Beaulieu, M.-È., & Soucek, L. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1723548 · Cited by 123
Camidge, D. R., Barlési, F., Goldman, J. W., Morgensztern, D., Heist, R. S., Vokes, E. E., Spira, A. I., Angevin, E., Su, W., Hong, D. S., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00739 · Cited by 127
Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs
Bayliss, R. W., Choi, J., Fennell, D. A., Fry, A. M., & Richards, M. W. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2117-6 · Cited by 127
Roszik, J., Haydu, L. E., Hess, K. R., Oba, J., Joon, A. Y., Siroy, A. E., Karpinets, T. V., Stingo, F. C., Baladandayuthapani, V., Tetzlaff, M. T., et al. (2016) · BMC Medicine · doi:10.1186/s12916-016-0705-4 · Cited by 115
Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy
Chalela, R., Curull, V., Enríquez-Rodríguez, C. J., Pijuán, L., Bellosillo, B., & Gea, J. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.06.20 · Cited by 129
Redefining the IBDs using genome-scale molecular phenotyping
Furey, T. S., Sethupathy, P., & Sheikh, S. Z. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0118-x · Cited by 129
Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo
Foggetti, G., Li, C., Cai, H., Hellyer, J. A., Lin, W.-Y., Ayeni, D. O., Hastings, K., Choi, J., Wurtz, A., Andrejka, L., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1385 · Cited by 119
Lehtiö, J., Arslan, T., Siavelis, I., Pan, Y., Socciarelli, F., Berkovska, O., Umer, H. M., Mermelekas, G., Pirmoradian, M., Jönsson, M., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00259-9 · Cited by 131
Steuer, C. E., Behera, M., Berry, L. D., Kim, S., Rossi, M. R., Sica, G., Owonikoko, T. K., Johnson, B. E., Kris, M. G., Bunn, P. A., et al. (2015) · Cancer · doi:10.1002/cncr.29812 · Cited by 121
Noncanonical GLI1 signaling promotes stemness features and in vivo growth in lung adenocarcinoma
Pò, A., Silvano, M., Miele, E., Capalbo, C., Eramo, A., Salvati, V., Todaro, M., Besharat, Z. M., Catanzaro, G., Cucchi, D., et al. (2017) · Oncogene · doi:10.1038/onc.2017.91 · Cited by 118
Choi, E.-J., Jung, B.-J., Lee, S.-H., Yoo, H.-S., Shin, E.-A., Ko, H., Chang, S., Kim, S.-Y., & Jeon, S.-M. (2017) · Oncogene · doi:10.1038/onc.2017.153 · Cited by 119
C-MET inhibitors for advanced non-small cell lung cancer
Pasquini, G., & Giaccone, G. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1462336 · Cited by 119
Cai, H., Jing, C., Chang, X., Ding, D., Han, T., Yang, J., Lu, Z., Hu, X., Liu, Z., Wang, J., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1941-0 · Cited by 119
Liu, C., Chen, Z., Chen, K., Liao, F.-T., Chung, C.-E., Liu, X., Lin, Y., Keohavong, P., Leikauf, G. D., & Di, Y. P. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1994 · Cited by 123
Concepcion, C. P., Ma, S., LaFave, L. M., Bhutkar, A. J., Liu, M., DeAngelo, L. P., Kim, J. Y., Priore, I. S. D., Schoenfeld, A. J., Miller, M., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0248 · Cited by 141
Pan-cancer analysis of whole genomes
Campbell, P. J., Getz, G., Stuart, J. M., Korbel, J. O., & Stein, L. D. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/162784 · Cited by 114
The lncRNA DRAIC / PCAT29 Locus Constitutes a Tumor-Suppressive Nexus
Sakurai, K., Reon, B. J., Anaya, J., & Dutta, A. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0016-t · Cited by 130
“Analysis of publicly available data from The Cancer Genome Atlas (TCGA) revealed that DRAIC is a predictor of good prognosis in at least seven other malignancies.”
BackgroundInfluentialKarlsson, A., Jönsson, M., Lauss, M., Brunnström, H., Jönsson, P., Borg, Å., Jönsson, G. B., Ringnér, M., Planck, M., & Staaf, J. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1087 · Cited by 120
The phosphoinositide 3-kinase pathway and therapy resistance in cancer
Brown, K. K., & Toker, A. (2015) · F1000Prime Reports · doi:10.12703/p7-13 · Cited by 111
The frequency and clinical impact of HER2 alterations in lung adenocarcinoma
Kim, E., Kim, K., Lee, C. Y., & Shim, H. S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171280 · Cited by 124
Baik, C. S., Myall, N. J., & Wakelee, H. A. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0458 · Cited by 113
Lineage-specific intolerance to oncogenic drivers restricts histological transformation
Gardner, E. E., Earlie, E. M., Li, K., Thomas, J., Hubisz, M. J., Stein, B. D., Zhang, C., Cantley, L. C., Laughney, A. M., & VARMUS, H. E. (2024) · Science · doi:10.1126/science.adj1415 · Cited by 124
“Hence, activating mutations and amplifications of genes that encode proteins in the mitogen-activated protein kinase (MAPK) pathway, including RAS and EGFR , are common in LUAD ( 15 ).”
BackgroundRicciuti, B., Alessi, J. V., Elkrief, A., Wang, X., Cortellini, A., Li, Y. Y., Vaz, V. R., Gupta, H., Pecci, F., Barrichello, A., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.07.005 · Cited by 112
Self-citationAn Arntl2-Driven Secretome Enables Lung Adenocarcinoma Metastatic Self-Sufficiency
Brady, J. J., Chuang, C.-H., Greenside, P. G., Rogers, Z. N., Murray, C. W., Caswell, D. R., Hartmann, U., Connolly, A. J., Sweet-Cordero, E. A., Kundaje, A., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.003 · Cited by 112
Unni, A. M., Harbourne, B., Oh, M. H., Wild, S. A., Ferrarone, J. R., Lockwood, W. W., & VARMUS, H. E. (2018) · eLife · doi:10.7554/elife.33718 · Cited by 123
EPISCORE: cell type deconvolution of bulk tissue DNA methylomes from single-cell RNA-Seq data
Teschendorff, A. E., Zhu, T., Breeze, C. E., & Beck, S. (2020) · Genome Biology · doi:10.1186/s13059-020-02126-9 · Cited by 112
Marzio, A., Kurz, E., Sahni, J. M., Di Feo, G., Puccini, J., Jiang, S., Hirsch, C. A., Arbini, A. A., Wu, W. L., Pass, H. I., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.005 · Cited by 110
Zhang, H., Liu, Z., Wen, H., Guo, Y., Xu, F., Zhu, Q., Yuan, W., Luo, R., Lu, C., Liu, R., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03173-w · Cited by 129
Gnanaprakasam, J. R., Kushwaha, B., Liu, L., Chen, X., Kang, S., Wang, T., Cassel, T., Adams, C. M., Higashi, R. M., Scott, D. A., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00856-1 · Cited by 121
The ERBB network facilitates KRAS-driven lung tumorigenesis
Kruspig, B., Monteverde, T., Neidler, S., Hock, A., Kerr, E., Nixon, C., Clark, W., Hedley, A., Laing, S., Coffelt, S. B., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao2565 · Cited by 111
Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy
Mandal, R., & Chan, T. A.-T. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0146 · Cited by 128
Norum, J., & Nieder, C. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000406 · Cited by 117
An LKB1–SIK Axis Suppresses Lung Tumor Growth and Controls Differentiation
Murray, C. W., Brady, J. J., Tsai, M. K., Li, C., Winters, I. P., Tang, R., Andrejka, L., Ma, R. K., Kunder, C. A., Chu, P., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1237 · Cited by 111
“We also examined the expression of these substrates in human lung adenocarcinoma and normal human lung (20).”
BackgroundMethodSitthideatphaiboon, P., Galan-Cobo, A., Negrao, M. V., Qu, X., Poteete, A., Zhang, F., Liu, D. D., Lewis, W. E., Kemp, H. N., Lewis, J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2859 · Cited by 111
Suzuki, A., Makinoshima, H., Wakaguri, H., Esumi, H., Sugano, S., Kohno, T., Tsuchihara, K., & Suzuki, Y. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku885 · Cited by 126
MicroRNA-31 initiates lung tumorigenesis and promotes mutant KRAS-driven lung cancer
Edmonds, M. D., Boyd, K. L., Moyo, T. K., Mitra, R., Duszynski, R. J., Arrate, M. P., Chen, X., Zhao, Z., Blackwell, T. S., Andl, T., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci82720 · Cited by 109
“Because mutant KRAS is the most common NSCLC driver mutation in tumors from patients with lung adenocarcinoma (7, 8), we tested whether miR-31 could cooperate with mutant KRAS in lung tumorigenesis.”
BackgroundInfluentialComprehensive Characterization of Oncogenic Drivers in Asian Lung Adenocarcinoma
Li, S., Choi, Y., Gong, Z., Liu, X., Lira, M. E., Kan, Z., Oh, E., Wang, J., Ting, J. C., Ye, X. S., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.08.142 · Cited by 123
Role of CPS1 in Cell Growth, Metabolism, and Prognosis in LKB1-Inactivated Lung Adenocarcinoma
Çeliktaş, M., Tanaka, I., Tripathi, S. C., Fahrmann, J. F., Aguilar-Bonavides, C., Villalobos, P. A., Delgado, O., Dhillon, D. S., Dennison, J. B., Ostrin, E. J., et al. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw231 · Cited by 117
Stueve, T. R., Li, W., Shi, J., Marconett, C. N., Zhang, T., Yang, C., Mullen, D. J., Yan, C., Wheeler, W., Hua, X., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx188 · Cited by 122
Targeting HER2 Aberrations in Non–Small Cell Lung Cancer with Osimertinib
Liu, S., Li, S., Hai, J., Wang, X., Chen, T., Quinn, M. M., Gao, P., Zhang, Y., Ji, H., Cross, D. A. E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1875 · Cited by 130
Dong, J., Li, B., Lin, D. C.-C., Zhou, Q., & Huang, D. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00230 · Cited by 123
Oka, M., Xu, L., Suzuki, T., Yoshikawa, T., Sakamoto, H., Uemura, H., Yoshizawa, A. C., Suzuki, Y., Nakatsura, T., Ishihama, Y., et al. (2021) · Genome Biology · doi:10.1186/s13059-020-02240-8 · Cited by 108
Hu, H., Cheng, R., Wang, Y., Wang, X., Wu, J., Kong, Y., Zhan, S., Zhou, Z., Zhu, H., Yu, R., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci153470 · Cited by 119
Targeting EGFR in Lung Cancer: Current Standards and Developments
Díaz-Serrano, A., Gella, P., Jiménez, E., Zugazagoitia, J., & Paz-Ares Rodríguez, L. (2018) · Drugs · doi:10.1007/s40265-018-0916-4 · Cited by 108
Wu, K., Zhang, X., Li, F., Xiao, D., Hou, Y., Zhu, S., Liu, D., Ye, X., Ye, M., Yang, J., et al. (2015) · Nature Communications · doi:10.1038/ncomms10131 · Cited by 115
Genotype and phenotype in patients with Noonan syndrome and a RIT1 mutation
Kouz, K., Lißewski, C., Spranger, S., Mitter, D., Rieß, A., López‐González, V., Lüttgen, S., Aydın, H., von Deimling, F., Evers, C., et al. (2016) · Genetics in Medicine · doi:10.1038/gim.2016.32 · Cited by 112
Prevalence and phenotypic correlations of EIF1AX mutations in thyroid nodules
Karunamurthy, A. D., Panebianco, F., Hsiao, S. J., Vorhauer, J., Nikiforova, M. N., Chiosea, S. I., & Nikiforov, Y. E. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0043 · Cited by 124
Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer
George, J., Saito, M., Tsuta, K., Iwakawa, R., Shiraishi, K., Scheel, A. H., Uchida, S., Watanabe, S.-I., Nishikawa, R., Noguchi, M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1069 · Cited by 108
Pereira, C., Gimenez-Xavier, P., Pros, E., Pajares, M. J., Moro, M., Gomez, A., Navarro, A., Condom, E., Moran, S., Gomez-Lopez, G., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1946 · Cited by 109
Schwaederle, M., Chattopadhyay, R., Kato, S., Fanta, P. T., Banks, K. C., Choi, I. S., Piccioni, D. E., Ikeda, S., Talasaz, A., Lanman, R. B., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0885 · Cited by 110
Mekonnen, N., Yang, H., & Shin, Y. K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.880643 · Cited by 137
Best, S. A., Ding, S., Kersbergen, A., Dong, X., Song, J.-Y., Xie, Y., Reljic, B., Li, K., Vince, J. E., Rathi, V., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12164-y · Cited by 108
Circulating Cell-Free Tumour DNA in the Management of Cancer
Francis, G. D., & Stein, S. R. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160614122 · Cited by 117
Conlon, N., da Silva, A., Guerra, E., Jelinic, P., Schlappe, B. A., Olvera, N., Mueller, J. J., Tornos, C. S., Jungbluth, A. A., Young, R. H., et al. (2015) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000558 · Cited by 108
Yin, X., Liao, H., Hong, Y., Lin, N., Li, S., Xiang, Y., & Ma, X. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.08.002 · Cited by 126
The DNA Damage Response and Inflammation in Cancer
Klapp, V., Álvarez-Abril, B., Leuzzi, G., Kroemer, G., Ciccia, A., & Galluzzi, L. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1220 · Cited by 123
Eng, J., Woo, K. M., Sima, C. S., Plodkowski, A., Hellmann, M. D., Chaft, J. E., Kris, M. G., Arcila, M. E., Ladanyi, M., & Drilon, A. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000671 · Cited by 107
MET Exon 14 Skipping in Non-Small Cell Lung Cancer
Heist, R. S., Shim, H. S., Gingipally, S., Mino-Kenudson, M. A., Le, L. P., Gainor, J. F., Zheng, Z., Aryee, M. J., Xia, J., Jia, P., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0510 · Cited by 121
TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients
Halvorsen, A. R., Silwal‐Pandit, L., Meza‐Zepeda, L. A., Vodák, D., Vu, P., Sagerup, C., Hovig, E. J., Myklebost, O., Børresen‐Dale, A., Brustugun, O. T., et al. (2016) · Frontiers in Genetics · doi:10.3389/fgene.2016.00085 · Cited by 110
Malone, C. F., Emerson, C. E., Ingraham, R., Barbosa, W. A., Guerra, S. L., Yoon, H., Liu, L. L., Michor, F., Haigis, M. C., Macleod, K. F., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0177 · Cited by 114
Genomic instability in mutant p53 cancer cells upon entotic engulfment
Mackay, H. L., Moore, D. A., Hall, C., Birkbak, N. J., Jamal‐Hanjani, M., Karim, S. A., Phatak, V. M., Piñon, L., Morton, J. P., Swanton, C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05368-1 · Cited by 117
Herreros‐Pomares, A., de-Maya-Girones, J. D., Fariñas, S. C., Lucas-Domínguez, R., Martínez‐Romero, A., Pardo-Sánchez, J. M., Alonso, S., Blasco, A., Guijarro, R., Martorell, M., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1898-1 · Cited by 120
Chang, J. C., Offin, M. D., Falcon, C. J., Brown, D. N., Houck-Loomis, B. R., Meng, F., Rudneva, V. A., Won, H. H., Amir, S., Montecalvo, J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0423 · Cited by 115
“The role of ERBB2 amplification as an oncogenic driver in lung adenocarcinoma is less well established, but is supported by prior studies (35, 36).”
ResultAn RFC4/Notch1 signaling feedback loop promotes NSCLC metastasis and stemness
Liu, L., Tao, T., Liu, S., Yang, X., Chen, X., Liang, J., Hong, R., Wang, W., Yang, Y., Li, X., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22971-x · Cited by 118
CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance
Nilsson, M. B., Yang, Y., Heeke, S., Patel, S. A., Poteete, A., Udagawa, H., Elamin, Y. Y., Moran, C. A., Kashima, Y., Arumugam, T., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.01.007 · Cited by 106
Rosendahl Huber, A., Pleguezuelos-Manzano, C., Puschhof, J., Ubels, J., Boot, C., Saftien, A., Verheul, M., Trabut, L. T., Groenen, N., van Roosmalen, M., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.02.009 · Cited by 106
ATM Deficiency Is Associated with Sensitivity to PARP1- and ATR Inhibitors in Lung Adenocarcinoma
Schmitt, A., Knittel, G., Welcker, D., Yang, T.-P., George, J., Nowak, M., Leeser, U., Büttner, R., Perner, S., Peifer, M., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3398 · Cited by 118
Exosomal lipids for classifying early and late stage non-small cell lung cancer
Fan, T. W. ‐., Zhang, X., Wang, C., Yang, Y., Kang, W.-Y., Arnold, S. M., Higashi, R. M., Liu, J., & Lane, A. N. (2018) · Analytica Chimica Acta · doi:10.1016/j.aca.2018.02.051 · Cited by 113
Circulating Tumor Cells in Diagnosis and Treatment of Lung Cancer
Malý, V., Malý, O., Kološtová, K., & Bobek, V. (2019) · In Vivo · doi:10.21873/invivo.11571 · Cited by 116
PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around
Γκουντάκος, Α., Sartori, G., Falcone, I., Piro, G., Ciuffreda, L., Carbone, C., Tortora, G., Scarpa, A., Bria, E., Milella, M., et al. (2019) · Cancers · doi:10.3390/cancers11081141 · Cited by 115
Rotow, J. K., Gui, P., Wu, W., Raymond, V. M., Lanman, R. B., Kaye, F. J., Peled, N., de la Cruz, F. F., Nadres, B., Corcoran, R. B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1667 · Cited by 113
Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumors
Wang, L., Yang, L., Wang, C., Wei, Z., Ju, Z., Zhang, W., Shen, J., Peng, Y., An, C., Luu, Y. T., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci130445 · Cited by 116
CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer
Gutiontov, S. I., Turchan, W. T., Spurr, L. F., Rouhani, S. J., Chervin, C. S., Steinhardt, G., Lager, A. M., Wanjari, P., Malik, R., Connell, P. P., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-99524-1 · Cited by 116
Reactive Oxygen Species and NRF2 Signaling, Friends or Foes in Cancer?
Wang, R., Liang, L., Matsumoto, M., Iwata, K., Umemura, A., & He, F. (2023) · Biomolecules · doi:10.3390/biom13020353 · Cited by 123
NetSig: network-based discovery from cancer genomes
Horn, H., Lawrence, M. S., Chouinard, C. R., Shrestha, Y., Hu, J. X., Worstell, E., Shea, E., Ilic, N., Kim, E., Kamburov, A., et al. (2018) · Nature Methods · doi:10.1038/nmeth.4514 · Cited by 105
Self-citationIdentification of NTRK fusions in pediatric mesenchymal tumors
Pavlick, D. C., Schrock, A. B., Malicki, D. M., Stephens, P. J., Kuo, D. J., Ahn, H., Turpin, B. K., Allen, J. M., Rosenzweig, M. R., Badizadegan, K., et al. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26433 · Cited by 105
Bergom, C. R., West, C., Higginson, D. S., Abazeed, M. E., Arun, B., Bentzen, S. M., Bernstein, J. L., Evans, J. D., Gerber, N. K., Kerns, S. L., et al. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2019.07.026 · Cited by 111
Prediction and Analysis of SARS-CoV-2-Targeting MicroRNA in Human Lung Epithelium
Chow, J. T.-S., & Salmena, L. (2020) · Genes · doi:10.3390/genes11091002 · Cited by 115
“To gain insight into the baseline levels of candidate miRNA in human lung epithelia, we curated miRNA expression data from 46 “normal” lung tissue specimens, which serve as control baseline samples in the TCGA-LUAD dataset [25].”
MethodWong, C. C., Baum, J., Silvestro, A., Beste, M. T., Bharani-Dharan, B., Xu, S., Wang, Y. A., Wang, X., Prescott, M. F., Krajkovich, L., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3176 · Cited by 105
“These differences may in part be due to the small sample size in this study, as well as concordance between ctDNA and tumor tissue mutation detection, the latter of which was used in the TCGA studies.”
BackgroundMethodResultInfluentialSex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion
Conforti, F., Pala, L., Pagan, E., Bagnardi, V., Pas, T. M. D., Queirolo, P., Pennacchioli, E., Catania, C., Cocorocchio, E., Ferrucci, P. F., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0136 · Cited by 120
Moving pan-cancer studies from basic research toward the clinic
Chen, F., Wendl, M. C., Wyczalkowski, M. A., Bailey, M. H., Li, Y., & Ding, L. (2021) · Nature Cancer · doi:10.1038/s43018-021-00250-4 · Cited by 115
Liang, W.-W., Lu, R. J.-H., Jayasinghe, R. G., Foltz, S. M., Porta-Pardo, E., Geffen, Y., Wendl, M. C., Lazcano, R., Kolodziejczak, I., Song, Y., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.07.013 · Cited by 105
Self-citationHaderk, F., Chou, Y.-T., Cech, L., Fernández-Méndez, C., Yu, J., Olivas, V., Meraz, I. M., Barbosa Rabago, D., Kerr, D. L., Gomez, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47423-0 · Cited by 103
OTUB1 triggers lung cancer development by inhibiting RAS monoubiquitination
Baietti, M. F., Šimíček, M., Asbagh, L. A., Radaelli, E., Lievens, S., Crowther, J., Steklov, M. Y., Aushev, V. N., Martínez‐García, D., Tavernier, J. H., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505972 · Cited by 111
Entropy-based consensus clustering for patient stratification
Liu, H., Zhao, R., Fang, H., Cheng, F., Fu, Y., & Liu, Y. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx167 · Cited by 110
Intratumoral immunoglobulin isotypes predict survival in lung adenocarcinoma subtypes
Isaeva, O. I., Sharonov, G. V., Serebrovskaya, E. O., Turchaninova, M. A., Zaretsky, A. R., Shugay, M., & Chudakov, D. M. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0747-1 · Cited by 108
Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation
Jenkins, R. W., Oxnard, G. R., Elkin, S. K., Sullivan, E. K., Carter, J. L., & Barbie, D. A. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2015.01.009 · Cited by 104
Vendrell, J. A., Taviaux, S. A., Béganton, B., Godreuil, S., Audran, P., Grand, D., Clermont, E., Serre, I., Szablewski, V., Coopman, P. J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-12679-8 · Cited by 104
Metadata
- Authors
- The Cancer Genome Atlas Research Network
- Venue
- Nature
- Published
- 2014-07-09
- Volume
- 511
- Issue
- 7511
- Pages
- 543-550
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4231481
- OpenAlex
- W2180481128
- Cited by
- 5,732
- References
- 42
- Citations by year
- 2026: 314 · 2025: 415 · 2024: 428 · 2023: 523 · 2022: 547 · 2021: 614 · 2020: 613 · 2019: 495 · 2018: 478 · 2017: 516 · 2016: 427 · 2015: 312 · 2014: 47
- FWCI
- 347.50
- Type
- journal article
- Language
- en
- Update notices
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)
- creativecommons.org/licenses/by-nc-sa/3.0/ (vor)
- Locations
- Nature (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nc-sa)
- SERVAL (Université de Lausanne) (acceptedVersion, cc-by-nc-sa)
- eScholarship (California Digital Library) (submittedVersion)
- IRIS (submittedVersion, cc-by-nc-sa)
- eSpace (Curtin University) (submittedVersion)
- Scholarworks@UNIST (Ulsan National Institute of Science and Technology) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health (UL1TR000005)
- National Human Genome Research Institute (U54HG003067, U54HG003079, U54HG003273, R01HG006272)
- National Cancer Institute (U24CA126554, U24CA143882, U24CA143843, U24CA143840, U24CA126546, CA143883, U24CA143858, K08CA137153, U24CA126543, U24CA144025, U24CA126563, U24CA143866, U24CA143883, CA143840, U24 CA137153, U24CA143845, U24CA126544, U24CA180951, U24CA143867, U24CA143848, U24CA143799, U24CA126551, U24CA143835, U24CA126561, P30CA177558, P30CA008748, P30CA016672, P30CA006973)
- National Institute of General Medical Sciences (T32GM007753)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- lung adenocarcinoma, somatic mutations, RIT1, MGA, MYC amplification, EGFR mutation, RBM10, neurofibromatosis type 1, MET, ERBB2, MET exon 14 skipping, splicing alterations, MAPK signaling, PI3K signaling, DNA methylation, microRNA, transcriptome, proteome, molecular classification, carcinogenesis
- MeSH terms
- Adenocarcinoma of Lung, Adenocarcinoma, Female, Humans, Lung Neoplasms, Male, Mutation, Oncogenes, Sex Factors, Gene Expression Regulation, Neoplastic, Gene Dosage, Cell Cycle Proteins, Genomics, Molecular Typing, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.